Valuation: Geron Corporation

Market Cap 61Cr 55Cr 50Cr 45Cr 86Cr 5.78TCr 88Cr 599.35Cr 239.66Cr 3.06TCr 229.75Cr 224.82Cr 9.67TCr P/E 2026 *
-21.6x
P/E 2027 * 14.4x
Enterprise Value 61Cr 55Cr 50Cr 45Cr 86Cr 5.78TCr 88Cr 599.35Cr 239.66Cr 3.06TCr 229.75Cr 224.82Cr 9.67TCr EV / Sales 2026 *
2.6x
EV / Sales 2027 * 1.79x
Free-Float
99.92%
Yield 2026 *
-
Yield 2027 * -
1 day+5.57%
1 week+11.10%
Current month+11.10%
1 month-17.88%
3 months-36.71%
6 months-37.11%
Current year-24.72%
1 week 0.88
Extreme 0.8847
1.09
1 month 0.84
Extreme 0.84
1.26
Current year 0.84
Extreme 0.84
2.01
1 year 0.84
Extreme 0.84
2.01
3 years 0.84
Extreme 0.84
5.34
5 years 0.84
Extreme 0.84
5.34
10 years 0.75
Extreme 0.75
6.99
Manager TitleAgeSince
Chief Executive Officer 55 07/08/2025
Director of Finance/CFO 59 25/09/2023
Chief Tech/Sci/R&D Officer - 01/10/2025
Director TitleAgeSince
Director/Board Member 76 21/05/2010
Director/Board Member 72 28/09/2012
Director/Board Member 55 26/03/2019
Date Insider Type Main position Quantity % Market Cap. Importance
30/09/26 Free

Director

6,351 0.0010%
30/06/26 Free

Director

6,103 0.0010%
20/05/26 Free

Director

2,20,000 0.0343%
Change 5-day change 1-year change 3-year change Capi.($)
+5.57%+11.10%-7.99%-46.29% 61Cr
-4.83%+2.88%+55.87%+69.12% 6.94TCr
-0.66%+0.32%+9.82%+75.36% 5.72TCr
-1.13%+3.26%+25.13%+100.72% 5.76TCr
+1.68%+1.28%+28.40%+36.47% 4.37TCr
+5.12%+9.20%+21.68%+106.18% 4.4TCr
+5.64%-2.82%+202.88%+763.09% 3.81TCr
-1.86%+11.46%+26.67%+61.40% 3.63TCr
-2.97%-9.89%+88.76%+76.07% 3.26TCr
-2.18%+5.68%+36.21%-0.69% 2.55TCr
Average +0.37%+3.16%+48.74%+124.14% 4.05TCr
Weighted average by Cap. -0.41%+2.45%+50.83%+135.55%

Financials

2026 *2027 *
Net sales 24Cr 21Cr 19Cr 17Cr 33Cr 2.22TCr 34Cr 230.46Cr 92Cr 1.18TCr 88Cr 86Cr 3.72TCr 34Cr 30Cr 28Cr 25Cr 48Cr 3.22TCr 49Cr 333.94Cr 133.53Cr 1.71TCr 128.01Cr 125.26Cr 5.39TCr
Net income -2.54Cr -2.26Cr -2.07Cr -1.89Cr -3.56Cr -240.12Cr -3.65Cr -25Cr -9.95Cr -127.17Cr -9.54Cr -9.33Cr -401.28Cr 3.77Cr 3.36Cr 3.08Cr 2.8Cr 5.28Cr 356.72Cr 5.42Cr 37Cr 15Cr 188.92Cr 14Cr 14Cr 596.13Cr
Net Debt - -
Projected Income Statement - Annual - Geron Corporation
Logo Geron Corporation
Geron Corporation is a commercial-stage biopharmaceutical company. The Company develops first-in-class telomerase inhibitor, RYTELO (imetelstat) for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (lower-risk MDS), with transfusion-dependent (TD) anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs). RYTELO is supported by the high unmet need in lower-risk MDS, including the observed benefit of RYTELO in difficult-to-treat subpopulations, such as patients with high transfusion burden and ring sideroblast negative (RS-) patients. It is also engaged in conducting a pivotal Phase III clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF), as well as studies in other myeloid hematologic malignancies.
Employees
258
Date Price Change Volume
06/26/06 $0.9961 +4.84% 28,52,893
05/26/05 $0.9501 -12.03% 2,58,33,003
04/26/04 $1.080 +16.13% 2,68,77,526
03/26/03 $0.9300 +0.10% 5,88,34,805
02/26/02 $0.9291 +3.88% 1,37,97,240
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Geron Corporation
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
0.9501USD
Average target price
3.625USD
Spread / Average Target
+281.54%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Geron Corporation
  1. Stock Market
  2. Stocks
  3. GERN Stock